Immobilized HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody, hFc Tag with the EC50 of 6.7 ng/ml determined by ELISA.
The purity of HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.
| Z06569 | |
|
|
|
| ￥9900 | |
|
|
|
|
|
|
| 联系我们 | |
